Skip to content

Advertisement

Open Peer Review Reports for: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
31 Dec 2016 Submitted Original manuscript
22 Feb 2017 Reviewed Reviewer Report - Herbert Loong
28 Feb 2017 Reviewed Reviewer Report - Christine Fillmore Brainson
9 Jul 2017 Author responded Author comments - Jianya Zhou
Resubmission - Version 2
9 Jul 2017 Submitted Manuscript version 2
14 Sep 2017 Reviewed Reviewer Report - Herbert Loong
8 Oct 2017 Author responded Author comments - Jianya Zhou
Resubmission - Version 3
8 Oct 2017 Submitted Manuscript version 3
Publishing
30 Oct 2017 Editorially accepted
3 Jan 2018 Article published 10.1186/s12885-017-3720-8

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement